Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit


WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024.

Read the rest here:
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Related Posts